One big question: With all the bidding for Guidant, why has there been no interest in St.
However, in March 2002, Guidant announced its home grown stent was ineffective and suspended trials.
Guidant chose the acquisition route, wisely leaving itself an out should Plan C fail.
In the meantime, Guidant and Cook oppose the ruling and Cook plans to appeal.
It is the 13th leading cause of death in the U.S., according to Guidant.
Guidant and other firms, including Transoma Medical and Germany's Biotronik, are all feverishly pursuing implanted sensors.
Weldon should be grateful that he failed in his attempt to buy medical device rival Guidant.
FORBES: Weldon's Legacy At J&J Goes Beyond Badly Made Baby Medicine
For two firms, Boston Scientific and Guidant , this research battle evolved into a nasty legal war.
But even if Cook's paclitaxel-coated stents prove medically effective, the plan may not save the day for Guidant.
Guidant, meanwhile, has suffered multiple setbacks in its drug-coated stent program, and is now far behind its competitors.
In 2001, Guidant and Cook entered into a distribution agreement, which Boston Scientific successfully challenged in June 2002.
Guidant said it would provide an update next week on the future of its abdominal aortic aneurism business.
The only question remaining revolved around Guidant's ability to use clinical data from Cook trials conducted before the acquisition.
When Guidant and Cook entered into the distribution agreement, Boston Scientific challenged it, saying that violated the original agreement.
Boston Scientific believes allowing Guidant to sell the paclitaxel-coated stent violates this agreement.
Cook subsequently entered into a distribution agreement with Guidant, which Boston Scientific claimed violated the co-exclusive agreement with Angiotech.
The rub: Guidant's partner, Cook , violated an earlier deal on the medical devices that also involved Boston Scientific.
This is not the first legal pitfall that Guidant has fallen into recently.
Chi-An Wang went on to a job at Guidant as a research engineer.
In a prepared statement, he argued that the new proposal was better for Guidant and its shareholders and can be closed quickly.
But some doctors and analysts say Guidant's devices are probably as safe, in general, as those made by other companies.
Guidant also announced that if the motion for a stay is denied, it will be revising guidance downward for 2003.
Rival Guidant takes it on the chin when a federal judge rules it cannot develop or sell its drug-coated stent.
Boston Scientific will likely file a preliminary injunction, thus stopping Cook's current sublicensing to Guidant regardless of the appeal filing.
Guidant and Boston Scientific now estimate that their stents will hit the U.S. market late next year or in early 2004.
The result: The judge says that all the research Guidant and Cook have poured into their suits must be thrown out.
Guidant's (nyse: GDT - news - people ) in-house-developed stent proved ineffective in March 2002, and trials were suspended.
Guidant also took a hit in 2003 over its Ancure aortic stent.
应用推荐